@article{14081a135af543219faca5bd307ee5e7,
title = "Cutaneous Lupus Erythematosus and Dermatomyositis: Utilizing Assessment Tools for Treatment Efficacy",
abstract = "There have been important developments in defining cutaneous lupus erythematosus and dermatomyositis. The skin manifestations of these two diseases have a profound impact on QOL, with both emotional and symptomatic impacts that are important to address. The proliferation of potential therapeutic targets has made it important to make sure that these diseases are defined in a way that they can be included in translational and clinical studies of both localized and systemic forms of the diseases. There are now validated disease tools and QOL studies that are facilitating current and future scientific and therapeutic developments.",
author = "Chong, {Benjamin F.} and Victoria Werth",
note = "Funding Information: This project is supported by the Department of Veterans Affairs Veterans Health Administration, Office of Research and Development , Biomedical Laboratory Research and Development , National Institutes of Health ( National Institute of Arthritis and Musculoskeletal and Skin Diseases , Bethesda, MD) R01AR071653 (BFC and VPW) and R01AR076766 (VPW). Funding Information: VPW has received grants from Pfizer, Corbus, Celgene, Amgen, Janssen, Biogen, Gilead, Viela; has consulted for Neovacs, Idera, Octapharma, CSL Behring, Corbus, Astra-Zeneca, Pfizer, Biogen, Celgene, Resolve, Janssen, Gilead, Lilly, BMS, Nektar, Abbvie, Akira, Viela, GSK, EMD Serona, and Sanofi; and developed and validated outcome measures for cutaneous lupus (CLASI) and dermatomyositis (CDASI). BFC is an investigator for Daavlin Corporation, Biogen Inc, Pfizer Inc, and Amgen Inc and a consultant for Viela Bio, Beacon Bioscience, Bristol Meyers Squibb, EMD Serono, and Principia Biopharma. Publisher Copyright: {\textcopyright} 2021 The Authors",
year = "2022",
month = mar,
doi = "10.1016/j.jid.2021.09.036",
language = "English (US)",
volume = "142",
pages = "936--943",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "3",
}